The issue of the admissibility of including human reproductive biomaterials temporarily separated from his body during the use of assisted reproductive technologies in the subject of contracts aimed at the transfer of ownership is subject to research. The article substantiates the position according to which neither singular nor universal succession is allowed in relation to germ cells, tissues of reproductive organs, as well as embryos obtained during the provision of medical services using ART. It has been established that the separation of the reproductive biomaterial from the human body (the originator) accompanies the infertility treatment of a couple or a single woman and does not pursue the goal of creating an object of law. The originator's object of interest is not a reproductive biomaterial that is temporarily separated from his body, but a medical organization's service that consists of performing a set of medical interventions aimed at preventing, diagnosing, and treating infertility. The persons from whom the reproductive biomaterial originates exercise control not over the biomaterial, but over their health, which results in a certain fate of germ cells and embryos in vitro. It is proved that the reproductive biomaterial lacks marketability properties, it is inextricably linked with the personality of the patients (recipients) undergoing treatment.